Browse the evidence

Adherence to digital GLP-1 RA-supported weight loss programs is significantly influenced by patient demographics, with older, Caucasian, and overweight individuals adhering significantly longer than younger, non-Caucasian, and higher BMI-class peers.

If you are using a digital GLP-1 program, be aware that adherence varies by demographic. Older, Caucasian, and overweight individuals in this study tended to stay in the program longer. However, the most common reasons for stopping are cost and side effects. To improve your chances of long-term success, proactively manage side effects with your care team and address financial concerns early, as these are the primary drivers of discontinuation.

In real-world digital weight loss programs combining behavioral therapy and GLP-1 receptor agonists (GLP-1 RAs), inadequate supply of the desired medication is the primary driver of patient discontinuation, outweighing cost and dissatisfaction with outcomes.

If you are using a digital weight loss program that includes GLP-1 medication, expect that medication supply issues are the most common reason for stopping treatment. To stay in the program, be prepared to discuss alternative medications with your care team if your preferred drug is unavailable, rather than discontinuing entirely. Also, consider the total value of the multidisciplinary support (doctors, dietitians, nurses) when evaluating the monthly cost, as cost is the second most common reason for dropping out.

Long-term participation in an intensive lifestyle intervention (ILI) for type 2 diabetes reduces reward-related neural reactivity to high-calorie food cues and enhances attention/visual processing compared to standard diabetes support.

If you have type 2 diabetes and are overweight, sticking to a structured lifestyle program (diet and exercise) for a long period can physically change how your brain reacts to high-calorie foods. Specifically, it may reduce the 'reward' signal and increase your brain's ability to pay attention to and process food cues consciously, which might support long-term weight management.

Online behavioral obesity treatment programs achieve higher implementation success in primary care when they are perceived as having high design quality, low cost, and strong compatibility with clinical workflows.

For primary care clinics adopting online weight loss tools, prioritize programs with clean, intuitive interfaces and zero cost to the provider. Ensure the tool fits seamlessly into existing workflows to avoid being deprioritized due to time constraints.

Trust in the intervention source (e.g., a local university) is a critical facilitator for clinician buy-in and patient enrollment in online obesity treatments.

When promoting online weight loss programs, explicitly highlight the affiliation with trusted local institutions (universities, hospitals) to overcome patient skepticism and clinician hesitation.

Clinician time savings and cost-effectiveness relative to commercial programs are key drivers for the successful implementation of online obesity treatments.

Emphasize to patients and providers that online programs are often free and do not require purchasing expensive specialty foods, making them more sustainable than commercial alternatives.

Early weight loss (first 14 days) in a behavioral weight management program predicts long-term weight loss trajectory patterns, specifically differentiating those who achieve sustained loss from those who do not, although it does not distinguish between different types of successful sustained loss patterns.

If you are starting a weight loss program, do not judge your success or failure in the first two weeks. The data shows that how much you lose in the first 14 days does not predict *how* you will lose weight long-term (steady vs. plateau), but it does predict *if* you will lose weight significantly. If you are not losing weight early, do not quit. Instead, focus on adherence. If you are losing weight, do not expect that fast loss will continue linearly. The key to long-term success is staying in the program for the long haul, regardless of the initial speed.

Sedentary behavior exceeding 9 hours per day significantly increases the odds of hypertension and diabetes, with stronger associations observed in socioeconomically vulnerable populations (Basic Livelihood Security recipients) compared to non-recipients.

If you sit for more than 9 hours a day, your risk for high blood pressure and diabetes increases significantly, especially if you have limited income. To mitigate this, do not sit continuously for long periods. Break up your sitting time with light activity, such as standing or walking for a few minutes, as this improves blood sugar control and vascular health even if you do not have time for formal exercise.

Comprehensive obesity care requires the integration of behavioral health support to address weight stigma, disordered eating, and the psychosocial impacts of large magnitude weight loss, which medical management alone cannot resolve.

Obesity treatment involves more than just weight loss; it includes managing the psychological impact of the disease. Seek out behavioral health support to address weight stigma, disordered eating, and the emotional changes that come with significant weight loss.

Health and wellness coaching (HWC) interventions for obesity and Type 2 Diabetes (T2D) demonstrate beneficial clinical findings, but current randomized controlled trials (RCTs) exhibit moderate design quality (average 56.7% score), with T2D studies showing significantly better intervention design fidelity than obesity studies.

Health coaching works for obesity and diabetes, but the quality of the coaching matters more than just the number of sessions. Look for coaches who are certified (NBHWC) and use structured behavior change strategies. For obesity, ensure the program is long-term (over 4 months) and includes frequent sessions, as these studies showed lower design quality and potentially less effective delivery compared to diabetes programs.

Increasing primary care provider (PCP) referral rates for weight loss surgery (WLS) significantly increases the volume of WLS procedures performed, with simulated interventions predicting up to a 24.1% increase in surgeries over 3 years.

If you are eligible for weight loss surgery, your primary care doctor's willingness to refer you is the biggest hurdle. This study suggests that simply encouraging your PCP to refer you to a specialist (endocrinologist or surgeon) significantly increases your chances of eventually having the surgery. If your PCP is hesitant, ask for a referral to a subspecialty obesity clinic, as this is a common stepping stone to surgery.

Bodybuilders primarily rely on fitness coaches and registered dietitians for information regarding dietary supplements, rather than independent medical advice or rigorous scientific literature.

When choosing supplements, prioritize advice from registered dietitians or nutritionists over fitness coaches, as coaches may lack specific nutritional expertise. This reduces the risk of misinformation and adverse effects.

Digital behavioral interventions are as effective as nondigital behavioral interventions for reducing overall cardiovascular risk factors, with no significant difference found across 11 key metrics.

You can use digital tools (apps, wearables, web platforms) to manage heart health risks just as effectively as traditional face-to-face programs or printed materials. The key is consistency and using evidence-based behavioral strategies, regardless of the delivery method.

High-risk patients on blood pressure, lipid, or glucose-lowering medications in primary care settings frequently fail to achieve guideline-recommended lifestyle and medical risk factor targets, indicating a significant gap between evidence-based guidelines and clinical practice.

If you are at high risk for heart disease, taking medication is not enough. You must also address lifestyle factors like smoking, weight, and physical activity. The study shows that most people on medication still fail to reach health targets. Focus on quitting smoking, maintaining a healthy weight, and staying active alongside your medical treatment.

Large-scale lifestyle interventions (diet and exercise) significantly reduce the risk of disease progression and microvascular complications in high-risk populations, but fail to significantly reduce macrovascular complications or mortality compared to usual care, primarily due to low adherence.

Lifestyle changes (diet and exercise) are highly effective at preventing diabetes progression and improving heart failure outcomes, but they often fail to extend life or prevent heart attacks in large groups because people struggle to stick with them long-term. To succeed, prioritize consistency and adherence over intensity, as the benefits are 'overwhelming' when you actually follow the plan.

Effective obesity prevention and treatment programs are more effective in children than in adults.

If you are trying to manage weight, know that interventions tend to work better for children. For adults, more complex or sustained strategies may be needed.

Having one or more chronic conditions (hypertension, dyslipidaemia, dysglycaemia, sleep apnoea, or depression) significantly decreases the odds of long-term retention in a commercial weight-loss program.

If you have chronic conditions like high blood pressure or diabetes, you are at higher risk of dropping out of a weight-loss program. Programs should screen for these conditions and offer targeted support to help you balance your health priorities.

Among patients with severe obesity treated with semaglutide 2.4 mg/week, those with higher intuitive eating scores and lower anxiety/depression levels (Intuitive Eaters Group) achieve significantly greater weight loss than those with higher emotional distress and lower intuitive eating scores (Emotionally Driven Eaters Group).

If you are taking semaglutide for severe obesity, your mental health and eating mindset matter for your results. Patients with high emotional distress and lower intuitive eating skills tend to lose less weight than those with better emotional regulation and intuitive eating habits. To maximize your weight loss, consider integrating psychological support or intuitive eating strategies alongside your medication, as these factors significantly influence your trajectory.

Treatment with the Epitomee shape-shifting hydrogel capsule combined with lifestyle intervention significantly improves health-related quality of life (HRQOL), specifically in Physical Function and total scores, compared to placebo in adults with overweight or obesity.

If you are overweight or have obesity (BMI 27-40) and struggle with portion control, this hydrogel capsule may help improve your quality of life and physical function more than lifestyle changes alone. You take one capsule with a large glass of water 30 minutes before your two main meals daily. It expands in your stomach to help you feel full sooner. This approach is particularly useful if you want to avoid medications or have contraindications to them. The benefits are most pronounced if you lose 10% or more of your body weight, but even modest loss improves physical function scores significantly.

Oral semaglutide is increasingly preferred by younger female patients with fewer comorbidities compared to subcutaneous semaglutide.

If you are a younger woman with few other health issues, you might be more likely to be prescribed oral semaglutide. This form is taken daily as a pill, which some patients prefer over weekly injections. Ensure you follow the specific administration instructions for oral semaglutide (taken on an empty stomach with water) to ensure effectiveness.

Black race and younger age are significantly associated with lower diet quality scores (AHEI-2010 and DASH) in this population, highlighting racial disparities in baseline diet quality.

If you are Black or younger, you may face specific challenges in maintaining a high-quality diet. The study shows these groups often have lower diet quality scores. Interventions should be tailored to address these specific disparities, such as improving access to healthy foods and culturally relevant nutrition education.

Mandibular advancement devices (MADs) provide symptom relief comparable to CPAP in mild-to-moderate OSA primarily due to superior long-term adherence, despite CPAP's superior objective efficacy in reducing AHI.

If you have mild-to-moderate sleep apnea and struggle with CPAP, ask about a mandibular advancement device. It might not reduce your apnea events as much as CPAP, but you are more likely to use it every night, which often leads to better overall health outcomes and symptom relief.

During COVID-19 stay-at-home mandates, older adults with type 2 diabetes experienced significant weight loss (average 2.1%) rather than the weight gain often reported in younger populations.

If you are an older adult with type 2 diabetes, do not assume the pandemic shutdown will automatically cause weight gain. This study found that the majority of participants actually lost weight. However, those who did gain weight reported more negative impacts on their health and access to food, so monitoring your weight and mental well-being is still important.

Among older adults with type 2 diabetes, those who gained weight during the pandemic reported significantly more negative psychosocial and behavioral impacts than those who lost weight.

If you gained weight during the pandemic, you are not alone, but you may be experiencing more stress, sleep issues, or access problems than those who lost weight. Focus on addressing these specific barriers (food access, sleep) rather than just the scale number. If you lost weight, it was likely intentional and not associated with the negative mental health impacts seen in gainers.